Succinate metabolism in cardiovascular diseases

¹ The Institute of Cardiovascular Sciences and Institute of Systems Biomedicine, School of Basic Medical Sciences, Key Laboratory of Molecular Cardiovascular Science of Ministry of Education, NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides, Beijing Key Laboratory of Cardiovascular Receptors Research, Health Science Center, Peking University

² Department of Cardiology and Institute of Vascular Medicine, Peking University Third Hospital; NHC Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides; Key Laboratory of Molecular Cardiovascular Science, Ministry of Education; Beijing Key Laboratory of Cardiovascular Receptors Research; Research Unit of Medical Science Research Management/Basic and Clinical Research of Metabolic Cardiovascular Diseases, Chinese Academy of Medical Sciences; Haihe Laboratory of Cell Ecosystem, Beijing 100 191, China

³ Beijing Tiantan Hospital National Clinical Research Center for Neurological Diseases, Advanced Innovation Center for Human Brain Protection, The Capital Medical University, Beijing 100 050, China

Global Translational Medicine 2022, 1(2), 160 https://doi.org/10.36922/gtm.v1i2.160

Submitted: 18 July 2022 | Accepted: 30 August 2022 | Published: 19 September 2022

© 2022 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Cardiovascular disease (CVD) refers to a class of diseases related to the heart or blood vessels that have high global incidence. Succinate is generally considered an important intermediate product of the tricarboxylic acid cycle. Recent studies have shown that succinate is related to the pathophysiology of CVD, such as atherosclerosis, acute aortic dissection, hypertension, myocardial ischemia-reperfusion injury, and heart failure. It may represent a potential target or biomarker for CVD. It has been demonstrated that succinate not only participates in various energy metabolic pathways but also plays an important role in various pathophysiological activities as a signaling molecule. Given the significance of metabolism in CVD, it is important to focus on the metabolic regulation mechanism of succinate in CVD. This review outlines the latest evidence pointing to the potential role of succinate in CVD, along with its mechanisms, and updates the current understanding on the role of succinate in CVD. Further studies may focus on identifying succinate, its receptor, and its downstream signaling molecules as new targets for the prevention and treatment of CVD.

Keywords

Cardiovascular diseases

Metabolism

Succinate

Succinate receptor 1

Funding

China Postdoctoral Science Foundation Grant

Conflict of interest

The authors declare that they have no competing interest.

References

[1]

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. 2017, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet, 390: 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2

[2]

Ren J, Bi Y, Sowers JR, et al., 2021, Endoplasmic reticulum stress and unfolded protein response in cardiovascular diseases. Nat Rev Cardiol, 18: 499–521. https://doi.org/10.1038/s41569-021-00511-w

[3]

Nishida K, Otsu K, 2017, Inflammation and metabolic cardiomyopathy. Cardiovasc Res, 113: 389–398. https://doi.org/10.1093/cvr/cvx012

[4]

Lussey-Lepoutre C, Hollinshead KE, Ludwig C. et al., 2015, Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun, 6: 8784. https://doi.org/10.1038/ncomms9784

[5]

Burch JS, Marcero JR, Maschek JA, et al., 2018, Glutamine via alpha-ketoglutarate dehydrogenase provides succinyl- CoA for heme synthesis during erythropoiesis. Blood, 132: 987–998. https://doi.org/10.1182/blood-2018-01-829036

[6]

Winther S, Trauelsen M, Schwartz TW, 2021, Protective succinate-SUCNR1 metabolic stress signaling gone bad. Cell Metab, 33: 1276–1278. https://doi.org/10.1016/j.cmet.2021.06.009

[7]

Martinez-Reyes I, Chandel NS, 2020, Mitochondrial TCA cycle metabolites control physiology and disease. Nat Commun, 11: 102. https://doi.org/10.1038/s41467-019-13668-3

[8]

Markevich NI, Galimova MH, Markevich LN, 2020, Hysteresis and bistability in the succinate-CoQ reductase activity and reactive oxygen species production in the mitochondrial respiratory complex II. Redox Biol, 37: 101630. https://doi.org/10.1016/j.redox.2020.101630

[9]

Wagner M, Bertero E, Nickel A, et al., 2020, Selective NADH communication from alpha-ketoglutarate dehydrogenase to mitochondrial transhydrogenase prevents reactive oxygen species formation under reducing conditions in the heart. Basic Res Cardiol, 115: 53. https://doi.org/10.1007/s00395-020-0815-1

[10]

Liu PS, Wang H, Li X, et al., 2017, Alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat Immunol, 18: 985–994. https://doi.org/10.1038/ni.3796

[11]

Alston CL, Davison JE, Meloni F, et al., 2012, Recessive germline SDHA and SDHB mutations causing leukodystrophy and isolated mitochondrial complex II deficiency. J Med Genet, 49: 569–577. https://doi.org/10.1136/jmedgenet-2012-101146

[12]

Acin-Perez R, Carrascoso I, Baixauli F, et al., 2014, ROS-triggered phosphorylation of complex II by Fgr kinase regulates cellular adaptation to fuel use. Cell Metab, 19: 1020–1033. https://doi.org/10.1016/j.cmet.2014.04.015

[13]

Kim SC, Sprung R, Chen Y, et al., 2006, Substrate and functional diversity of lysine acetylation revealed by a proteomics survey. Mol Cell, 23: 607–618. https://doi.org/10.1016/j.molcel.2006.06.026

[14]

Du J, Zhou Y, Su X, et al., 2011, Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science, 334: 806–809. https://doi.org/10.1126/science.1207861

[15]

Faith JJ, Ahern PP, Ridaura VK, et al., 2014, Identifying gut microbe-host phenotype relationships using combinatorial communities in gnotobiotic mice. Sci Transl Med, 6: 220ra211. https://doi.org/10.1126/scitranslmed.3008051

[16]

Macy JM, Ljungdahl LG, Gottschalk G, 1978, Pathway of succinate and propionate formation in Bacteroides fragilis. J Bacteriol, 134: 84–91. https://doi.org/10.1128/jb.134.1.84-91.1978

[17]

De Vadder F, Kovatcheva-Datchary P, Zitoun C, et al., 2016, Microbiota-produced succinate improves glucose homeostasis via intestinal gluconeogenesis. Cell Metab, 24: 151–157. https://doi.org/10.1016/j.cmet.2016.06.013

[18]

De Vadder F, Kovatcheva-Datchary P, Goncalves D, et al., 2014, Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell, 156: 84–96. https://doi.org/10.1016/j.cell.2013.12.016

[19]

Watanabe Y, Nagai F, Morotomi M, 2012, Characterization of phascolarctobacterium succinatutens sp. nov., an asaccharolytic, succinate-utilizing bacterium isolated from human feces. Appl Environ Microbiol, 78: 511–518. https://doi.org/10.1128/AEM.06035-11

[20]

Fernandez-Veledo S, Vendrell J, 2019, Gut microbiota-derived succinate: Friend or foe in human metabolic diseases? Rev Endocr Metab Disord, 20: 439–447. https://doi.org/10.1007/s11154-019-09513-z

[21]

Connors J, Dawe N, Van Limbergen J, 2018, The role of succinate in the regulation of intestinal inflammation. Nutrients, 11: 25. https://doi.org/10.3390/nu11010025

[22]

Ariake K, Ohkusa T, Sakurazawa T, et al., 2000, Roles of mucosal bacteria and succinic acid in colitis caused by dextran sulfate sodium in mice. J Med Dent Sci, 47: 233–241.

[23]

Tannahill GM, Curtis AM, Adamik J, et al., 2013, Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature, 496: 238–242. https://doi.org/10.1038/nature11986

[24]

Chouchani ET, Pell VR, Gaude E, et al., 2014, Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature, 515: 431–435. https://doi.org/10.1038/nature13909

[25]

Mills E, O’Neill LA, 2014, Succinate: A metabolic signal in inflammation. Trends Cell Biol, 24: 313–320. https://doi.org/10.1016/j.tcb.2013.11.008

[26]

Reddy A, Bozi LH, Yaghi OK, et al., 2020, pH-gated succinate secretion regulates muscle remodeling in response to exercise. Cell, 183: 62–75 e17. https://doi.org/10.1016/j.cell.2020.08.039

[27]

An YA, Chen S, Deng Y, et al., 2021, The mitochondrial dicarboxylate carrier prevents hepatic lipotoxicity by inhibiting white adipocyte lipolysis. J Hepatol, 75: 387–399. https://doi.org/10.1016/j.jhep.2021.03.006

[28]

Prag HA, Gruszczyk AV, Huang MM, et al., 2021, Mechanism of succinate efflux upon reperfusion of the ischaemic heart. Cardiovasc Res, 117: 1188–1201. https://doi.org/10.1093/cvr/cvaa148

[29]

Bisbach CM, Hass DT, Thomas ED, et al., 2022, Monocarboxylate transporter 1 (MCT1) mediates succinate export in the retina. Invest Ophthalmol Vis Sci, 63: 1. https://doi.org/10.1167/iovs.63.4.1

[30]

He W, Miao FJ, Lin DC, et al., 2004, Citric acid cycle intermediates as ligands for orphan G-protein-coupled receptors. Nature, 429: 188–193. https://doi.org/10.1038/nature02488

[31]

Haffke M, Fehlmann D, Rummel G, et al., 2019, Structural basis of species-selective antagonist binding to the succinate receptor. Nature, 574: 581–585. https://doi.org/10.1038/s41586-019-1663-8

[32]

Macaulay IC, Tijssen MR, Thijssen-Timmer DC, et al., 2007, Comparative gene expression profiling of in vitro differentiated megakaryocytes and erythroblasts identifies novel activatory and inhibitory platelet membrane proteins. Blood, 109: 3260–3269. https://doi.org/10.1182/blood-2006-07-036269

[33]

Rubic T, Lametschwandtner G, Jost S, et al., 2008, Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat Immunol, 9: 1261–1269. https://doi.org/10.1038/ni.1657

[34]

Saraiva AL, Veras FP, Peres RS, et al., 2018, Succinate receptor deficiency attenuates arthritis by reducing dendritic cell traffic and expansion of Th17 cells in the lymph nodes. FASEB J, 32: 6550–6558. https://doi.org/10.1096/fj.201800285

[35]

Trauelsen M, Rexen Ulven E, Hjorth SA, et al., 2017, Receptor structure-based discovery of non-metabolite agonists for the succinate receptor GPR91. Mol Metab, 6: 1585–1596. https://doi.org/10.1016/j.molmet.2017.09.005

[36]

Littlewood-Evans A, Sarret S, Apfel V, et al., 2016, GPR91 senses extracellular succinate released from inflammatory macrophages and exacerbates rheumatoid arthritis. J Exp Med, 213: 1655–1662. https://doi.org/10.1084/jem.20160061

[37]

van Diepen JA, Robben JH, Hooiveld GJ, et al., 2017, SUCNR1-mediated chemotaxis of macrophages aggravates obesity-induced inflammation and diabetes. Diabetologia, 60: 1304–1313. https://doi.org/10.1007/s00125-017-4261-z

[38]

Harber KJ, de Goede KE, Verberk SG, et al., 2020, Succinate is an inflammation-induced immunoregulatory metabolite in macrophages. Metabolites, 10: 372. https://doi.org/10.3390/metabo10090372

[39]

Fernandez-Veledo S, Ceperuelo-Mallafre V, Vendrell J, 2021, Rethinking succinate: An unexpected hormone-like metabolite in energy homeostasis. Trends Endocrinol Metab, 32: 680–692. https://doi.org/10.1016/j.tem.2021.06.003

[40]

Xu J, Zheng Y, Zhao Y, et al., 2022, Succinate/IL-1beta signaling axis promotes the inflammatory progression of endothelial and exacerbates atherosclerosis. Front Immunol, 13: 817572. https://doi.org/10.3389/fimmu.2022.817572

[41]

Chen J, Zhang J, Wu J, et al., 2021, Low shear stress induced vascular endothelial cell pyroptosis by TET2/SDHB/ROS pathway. Free Radic Biol Med, 162: 582–591. https://doi.org/10.1016/j.freeradbiomed.2020.11.017

[42]

Wu P, Chen J, Chen J, et al., 2020, Trimethylamine N-oxide promotes apoE(-/-) mice atherosclerosis by inducing vascular endothelial cell pyroptosis via the SDHB/ROS pathway. J Cell Physiol, 235: 6582–6591. https://doi.org/10.1002/jcp.29518

[43]

Mills EL, Kelly B, Logan A, et al., 2016, Succinate dehydrogenase supports metabolic repurposing of mitochondria to drive inflammatory macrophages. Cell, 167: 457–470 e413. https://doi.org/10.1016/j.cell.2016.08.064

[44]

Ming-Chin Lee K, Achuthan AA, De Souza DP, et al., 2022, Type I interferon antagonism of the JMJD3-IRF4 pathway modulates macrophage activation and polarization. Cell Rep, 39: 110719. https://doi.org/10.1016/j.celrep.2022.110719

[45]

Wu JY, Huang TW, Hsieh YT, et al., 2020, Cancer-derived succinate promotes macrophage polarization and cancer metastasis via succinate receptor. Mol Cell, 77: 213–227 e215. https://doi.org/10.1016/j.molcel.2019.10.023

[46]

Sampson UK, Norman PE, Fowkes FG, et al., 2014, Global and regional burden of aortic dissection and aneurysms: Mortality trends in 21 world regions, 1990 to 2010. Glob Heart, 9: 171–180 e110. https://doi.org/10.1016/j.gheart.2013.12.010

[47]

Cui H, Chen Y, Li K, et al., 2021, Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection. Eur Heart J, 42: 4373–4385. https://doi.org/10.1093/eurheartj/ehab605

[48]

Toma I, Kang JJ, Sipos A, et al., 2008, Succinate receptor GPR91 provides a direct link between high glucose levels and renin release in murine and rabbit kidney. J Clin Invest, 118: 2526–2534. https://doi.org/10.1172/JCI33293

[49]

Vargas SL, Toma I, Kang JJ, et al., 2009, Activation of the succinate receptor GPR91 in macula densa cells causes renin release. J Am Soc Nephrol, 20: 1002–1011. https://doi.org/10.1681/ASN.2008070740

[50]

Robben JH, Fenton RA, Vargas SL, et al., 2009, Localization of the succinate receptor in the distal nephron and its signaling in polarized MDCK cells. Kidney Int, 76: 1258–1267. https://doi.org/10.1038/ki.2009.360

[51]

Sadagopan N, Li W, Roberds SL, et al., 2007, Circulating succinate is elevated in rodent models of hypertension and metabolic disease. Am J Hypertens, 20: 1209–1215. https://doi.org/10.1016/j.amjhyper.2007.05.010

[52]

Khamaysi A, Anbtawee-Jomaa S, Fremder M, et al., 2019, Systemic succinate homeostasis and local succinate signaling affect blood pressure and modify risks for calcium oxalate lithogenesis. J Am Soc Nephrol, 30: 381–392. https://doi.org/10.1681/ASN.2018030277

[53]

Milliken AS, Nadtochiy SM, Brookes PS, 2022, Inhibiting succinate release worsens cardiac reperfusion injury by enhancing mitochondrial reactive oxygen species generation. J Am Heart Assoc, 11: e026135. https://doi.org/10.1161/JAHA.122.026135

[54]

Lu YT, Li LZ, Yang YL, et al., 2018, Succinate induces aberrant mitochondrial fission in cardiomyocytes through GPR91 signaling. Cell Death Dis, 9: 672. https://doi.org/10.1038/s41419-018-0708-5

[55]

Pell VR, Chouchani ET, Frezza C, et al., 2016, Succinate metabolism: A new therapeutic target for myocardial reperfusion injury. Cardiovasc Res, 111: 134–141. https://doi.org/10.1093/cvr/cvw100

[56]

Bae J, Salamon RJ, Brandt EB, et al., 2021, Malonate promotes adult cardiomyocyte proliferation and heart regeneration. Circulation, 143: 1973–1986. https://doi.org/10.1161/CIRCULATIONAHA.120.049952

[57]

Valls-Lacalle L, Barba I, Miro-Casas E, et al., 2018, Selective inhibition of succinate dehydrogenase in reperfused myocardium with intracoronary malonate reduces infarct size. Sci Rep, 8: 2442. https://doi.org/10.1038/s41598-018-20866-4

[58]

Xu J, Pan H, Xie X, et al., 2018, Inhibiting succinate dehydrogenase by dimethyl malonate alleviates brain damage in a rat model of cardiac arrest. Neuroscience, 393: 24–32. https://doi.org/10.1016/j.neuroscience.2018.09.041

[59]

Martin JL, Costa AS, Gruszczyk AV, et al., 2009, Succinate accumulation drives ischaemia-reperfusion injury during organ transplantation. Nat Metab, 1: 966–974. https://doi.org/10.1038/s42255-019-0115-y

[60]

Wyss RK, Mendez Carmona N, Arnold M, et al., 2021, Hypothermic, oxygenated perfusion (HOPE) provides cardioprotection via succinate oxidation prior to normothermic perfusion in a rat model of donation after circulatory death (DCD). Am J Transplant, 21: 1003–1011. https://doi.org/10.1111/ajt.16258

[61]

Kolwicz SC Jr., Purohit S, Tian R, 2013, Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes. Circ Res, 113: 603–616. https://doi.org/10.1161/CIRCRESAHA.113.302095

[62]

Aguiar CJ, Rocha-Franco JA, Sousa PA, et al., 2014, Succinate causes pathological cardiomyocyte hypertrophy through GPR91 activation. Cell Commun Signal, 12: 78. https://doi.org/10.1186/s12964-014-0078-2

[63]

Yang L, Yu D, Mo R, et al., 2016, The succinate receptor GPR91 is involved in pressure overload-induced ventricular hypertrophy. PLoS One, 11: e0147597. https://doi.org/10.1371/journal.pone.0147597

[64]

Davili Z, Johar S, Hughes C, et al., 2007, Succinate dehydrogenase deficiency associated with dilated cardiomyopathy and ventricular noncompaction. Eur J Pediatr, 166: 867–870. https://doi.org/10.1007/s00431-006-0310-1

[65]

Aguiar CJ, Andrade VL, Gomes ER, et al., 2010, Succinate modulates Ca(2+) transient and cardiomyocyte viability through PKA-dependent pathway. Cell Calcium, 47: 37–46. https://doi.org/10.1016/j.ceca.2009.11.003

[66]

Banerjee P, Bandyopadhyay A, 2014, Cytosolic dynamics of annexin A6 trigger feedback regulation of hypertrophy via atrial natriuretic peptide in cardiomyocytes. J Biol Chem, 289: 5371–5385. https://doi.org/10.1074/jbc.M113.514810

[67]

Palomer X, Salvado L, Barroso E, et al., 2013, An overview of the crosstalk between inflammatory processes and metabolic dysregulation during diabetic cardiomyopathy. Int J Cardiol, 168: 3160–3172. https://doi.org/10.1016/j.ijcard.2013.07.150

[68]

Singh T, Khan H, Gamble DT, et al., 2022, Takotsubo syndrome: Pathophysiology, emerging concepts, and clinical implications. Circulation, 145: 1002–1019. https://doi.org/10.1161/CIRCULATIONAHA.121.055854

[69]

Keiran N, Ceperuelo-Mallafre V, Calvo E, et al., 2019, SUCNR1 controls an anti-inflammatory program in macrophages to regulate the metabolic response to obesity. Nat Immunol, 20: 581–592. https://doi.org/10.1038/s41590-019-0372-7

[70]

Ceperuelo-Mallafre V, Llaurado G, Keiran N, et al., 2019, Preoperative circulating succinate levels as a biomarker for diabetes remission after bariatric surgery. Diabetes Care, 42: 1956–1965. https://doi.org/10.2337/dc19-0114

[71]

Mills EL, Pierce KA, Jedrychowski MP, et al., 2018, Accumulation of succinate controls activation of adipose tissue thermogenesis. Nature, 560: 102–106. https://doi.org/10.1038/s41586-018-0353-2

[72]

Mills EL, Harmon C, Jedrychowski MP, et al., 2021, UCP1 governs liver extracellular succinate and inflammatory pathogenesis. Nat Metab, 3: 604–617. https://doi.org/10.1038/s42255-021-00389-5

[73]

Liu X, Chen Y, Zhao L, et al., 2022, Dietary succinate supplementation to maternal mice improves fetal brown adipose tissue development and thermogenesis of female offspring. J Nutr Biochem, 100: 108908. https://doi.org/10.1016/j.jnutbio.2021.108908

[74]

Liu K, Lin L, Li Q, et al., 2020, Scd1 controls de novo beige fat biogenesis through succinate-dependent regulation of mitochondrial complex II. Proc Natl Acad Sci U S A, 117: 2462–2472. https://doi.org/10.1073/pnas.1914553117

[75]

Regard JB, Sato IT, Coughlin SR, 2008, Anatomical profiling of G protein-coupled receptor expression. Cell, 135: 561–571. https://doi.org/10.1016/j.cell.2008.08.040

[76]

McCreath KJ, Espada S, Galvez BG, et al., 2015, Targeted disruption of the SUCNR1 metabolic receptor leads to dichotomous effects on obesity. Diabetes, 64: 1154–1167. https://doi.org/10.2337/db14-0346

[77]

Rexen Ulven E, Trauelsen M, Brvar M, et al., 2018, Structure-activity investigations and optimisations of non-metabolite agonists for the succinate receptor 1. Sci Rep, 8: 10010. https://doi.org/10.1038/s41598-018-28263-7

[78]

Geubelle P, Gilissen J, Dilly S, et al., 2017, Identification and pharmacological characterization of succinate receptor agonists. Br J Pharmacol, 174: 796–808. https://doi.org/10.1111/bph.13738

[79]

Bhuniya D, Umrani D, Dave B, et al., 2011, Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg Med Chem Lett, 21: 3596–3602. https://doi.org/10.1016/j.bmcl.2011.04.091

[80]

Sakai M, Sumiyoshi T, Aoyama T, et al., 2020, GPR91 antagonist and TGF-beta inhibitor suppressed collagen production of high glucose and succinate induced HSC activation. Biochem Biophys Res Commun, 530: 362–366. https://doi.org/10.1016/j.bbrc.2020.07.141

[81]

Le CT, Nguyen G, Park SY, et al., 2018, LY2405319, an analog of fibroblast growth factor 21 ameliorates alpha-smooth muscle actin production through inhibition of the succinate-G-protein couple receptor 91 (GPR91) pathway in mice. PLoS One, 13: e0192146. https://doi.org/10.1371/journal.pone.0192146

[82]

Nguyen G, Park SY, Le CT, et al., 2018, Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition. Biochem Biophys Res Commun, 495: 2649–2656. https://doi.org/10.1016/j.bbrc.2017.12.143

[83]

Zhang H, Zheng J, Lin J, et al., 2018, miR-758 mediates oxLDL-dependent vascular endothelial cell damage by suppressing the succinate receptor SUCNR1. Gene, 663: 1–8. https://doi.org/10.1016/j.gene.2018.04.029

[84]

Li T, Hu J, Gao F, et al., 2017, Transcription factors regulate GPR91-mediated expression of VEGF in hypoxia-induced retinopathy. Sci Rep, 7: 45807. https://doi.org/10.1038/srep45807

[85]

Osuna-Prieto FJ, Martinez-Tellez B, Ortiz-Alvarez L, et al., 2021, Elevated plasma succinate levels are linked to higher cardiovascular disease risk factors in young adults. Cardiovasc Diabetol, 20: 151. https://doi.org/10.1186/s12933-021-01333-3

[86]

Serena C, Ceperuelo-Mallafre V, Keiran N, et al., 2018, Elevated circulating levels of succinate in human obesity are linked to specific gut microbiota. ISME J, 12: 1642–1657. https://doi.org/10.1038/s41396-018-0068-2

Previous article in this issue

Next article in this issue

Global Translational Medicine, Electronic ISSN: 2811-0021 Print ISSN: 3060-8600, Published by AccScience Publishing